Precision BioSciences, Inc.
302 East Pettigrew Street
About Precision BioSciences, Inc.
Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com
Stock Symbol: DTIL
Stock Exchange: NASDAQ
Precision BioSciences: Culture
237 articles about Precision BioSciences, Inc.
Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting
Precision BioSciences, Inc. (Nasdaq: DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced today that initial results from the ongoing Phase 1/2a trial of its lead investigational off-the-shelf (allogeneic) chimeric antigen receptor (CAR) T cell therapy candidate, PBCAR0191, will be presented during the 61st Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, December 7-10, 2019.
Precision BioSciences to Report Third Quarter 2019 Financial Results and Present at Upcoming Investor Conferences in November
Precision BioSciences, Inc., a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced that it will publish financial results for the third quarter of 2019 and provide a corporate update on November 12, 2019.
9/30/2019It was a moderately busy week for clinical trial news. Here’s a look.
This week has marked a number of stories over construction projects and real estate developers focused on the life sciences market. Here’s a look.
Precision BioSciences Opens First In-House cGMP Manufacturing Facility Dedicated to Genome-Edited Allogeneic CAR T Cell Therapy in the United States
Research Triangle Park Facility to Manufacture Precision’s Pipeline of Off-the-Shelf CAR T Product Candidates to Support Clinical Trials
Great Place to Work is an organization whose goal it is to assure that all people in the U.S. have a great place to work by 2030. One category for certified companies is Biotechnology & Pharmaceuticals, which listed 36 companies. BioSpace organized these 36 companies into its BioSpace Hotbed Regi...
Durham, NC-based Precision BioSciences set its initial public offering (IPO) price at $16 per share, raising $126.4 million. It began trading today on the Nasdaq under the ticker symbol DTIL.
A summary of IPOs from companies in the biotech and pharma world since March 1, 2019.
March has been a busy month for biopharma and medical device company initial public offerings. Here’s a look at the top IPO stories for the month.
3/15/2019Biotech and pharma companies make changes to their executive leadership teams, with moves at Sandoz, PAREXEL, FSD, Karuna, Precision Bio, and more.
Globally recognized leader in antiviral drug discovery and development
Precision BioSciences announced that it has entered into an agreement for the issuance and sale of convertible promissory notes in a private placement transaction in the aggregate principal amount of approximately $40 million, which will bring the Company’s total capital generated in the last year to over $150 million and total funding since inception to over $300 million.
Durham, NC-based Precision BioSciences filed on Friday with the U.S. Securities Exchange Commission for an initial public offering (IPO). The company, which focuses on gene-edited CAR-T cell therapies for cancer, plans to raise $100 million.
Precision BioSciences Announces Formation of Scientific Advisory Board with Anderson, Kantarjian, Schinazi and Turtle
Precision BioSciences today announced the formation of its Scientific Advisory Board (SAB) with four key appointments: Kenneth C. Anderson, M.D., Hagop Kantarjian, M.D., Raymond Schinazi, Ph.D., D.Sc. and Cameron Turtle, MBBS, Ph.D.
Sharp brings a wealth of experience in financial management and corporate strategy in rare disease, gene therapy and oncology.
Precision BioSciences and Durham STEM Students Lead Launch of First Genome Editing Experiment Into Space
SpaceX Falcon 9 Delivering ARCUS Gene Editing to the International Space Station
Precision BioSciences Receives FDA Authorization to Initiate Clinical Study of Gene Edited Cancer Immunotherapy
Precision BioSciences and Servier today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for PBCAR0191, an allogeneic anti-CD19 CAR T therapy for B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL).
Precision BioSciences gains rights to MaxCyte's cell engineering technology to develop next-generation, oncology-focused, cell therapies with Precision's ARCUS® genome-editing technology
The Baltimore Longitudinal Study of Aging was launched in 1958 by the National Institutes of Health. The idea was to follow and study the lives of healthy, active people over their lifetimes, rather than after they were dead.
Elo Life Systems has opened a new Australian location at the Queensland University of Technology (QUT), Gardens Point Campus in Brisbane.